Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma.
de la Puente P, Luderer MJ, Federico C, Jin A, Gilson RC, Egbulefu C, Alhallak K, Shah S, Muz B, Sun J, King J, Kohnen D, Salama NN, Achilefu S, Vij R, Azab AK. de la Puente P, et al. Among authors: vij r. J Control Release. 2018 Jan 28;270:158-176. doi: 10.1016/j.jconrel.2017.11.045. Epub 2017 Nov 28. J Control Release. 2018. PMID: 29196043 Free PMC article.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. Vij R, et al. Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3. Blood. 2012. PMID: 22555973 Free PMC article. Clinical Trial.
The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN. Hurchla MA, et al. Among authors: vij r. Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5. Leukemia. 2013. PMID: 22763387 Free PMC article.
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. Vij R, et al. Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30. Br J Haematol. 2012. PMID: 22845873 Free PMC article. Clinical Trial.
Carfilzomib in multiple myeloma.
Vij R. Vij R. Clin Adv Hematol Oncol. 2012 Sep;10(9):591-3. Clin Adv Hematol Oncol. 2012. PMID: 23073124 No abstract available.
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R. Wang TF, et al. Among authors: vij r. Leuk Lymphoma. 2014 Feb;55(2):337-41. doi: 10.3109/10428194.2013.803547. Epub 2013 Jun 24. Leuk Lymphoma. 2014. PMID: 23662990 Free PMC article.
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance.
Azab F, Vali S, Abraham J, Potter N, Muz B, de la Puente P, Fiala M, Paasch J, Sultana Z, Tyagi A, Abbasi T, Vij R, Azab AK. Azab F, et al. Among authors: vij r. Br J Haematol. 2014 Apr;165(1):89-101. doi: 10.1111/bjh.12734. Epub 2014 Jan 9. Br J Haematol. 2014. PMID: 24405121 Free article.
Personalization of cancer treatment using predictive simulation.
Doudican NA, Kumar A, Singh NK, Nair PR, Lala DA, Basu K, Talawdekar AA, Sultana Z, Tiwari KK, Tyagi A, Abbasi T, Vali S, Vij R, Fiala M, King J, Perle M, Mazumder A. Doudican NA, et al. Among authors: vij r. J Transl Med. 2015 Feb 1;13:43. doi: 10.1186/s12967-015-0399-y. J Transl Med. 2015. PMID: 25638213 Free PMC article.
433 results